Primary Care Respiratory Society UK (PCRS-UK)

Username:   Password:
Remember me on this computer
(won't work if cookies are not enabled in browser)



COPD National Strategy: First Steps - How Ready Are You?
Individual Knowledge Test

Introduction
Take a quick 10-question survey to test your knowledge on some of the clinical aspects of managing COPD.

When you have completed the survey, click on the Submit button at the bottom of the page.

You will then see a display with the answers you selected shown in red.

The correct answers will be highlighted in blue.

Background information will be displayed below each answer where available.

Are you a member of the Primary Care Respiratory Society UK?

What is your profession?

If Other, please specify:

Are you a respiratory lead?

If you are not a respiratory lead, is there a respiratory lead in your practice?


Top of page | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | References and Abbreviations |

1. Which of the following is a feature of COPD in symptomatic patients?
a. Haemoptysis
b. Increased breathlessness at night
c. Increased breathlessness on exertion
d. Wide variation in exercise tolerance
e. Wheeze at rest


Top of page | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | References and Abbreviations |

2. Which of the following conditions are more commonly found in people with COPD than in the general population?
More than one answer allowed.
 a. Coronary Heart Disease
 b. Osteoporosis
 c. Diabetes
 d. Cancer
 e. Anxiety/depression


Top of page | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | References and Abbreviations |

3. Which of the following lung function parameters would you use to confirm a clinically suspected diagnosis of airflow obstruction in a patient?
More than one answer allowed.
 a. PEF*
 b. FEV1**/FVC*** ratio
 c. FEV1/VC† ratio
 d. FEV1 % predicted


Top of page | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | References and Abbreviations |

4. Which of the following parameters would you use to classify the severity of airflow obstruction?
a. FVC
b. FEV1 % predicted
c. VC
d. FEV1/FVC


Top of page | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | References and Abbreviations |

5. In a patient with diagnosed COPD, which of the following would influence your decision to offer a trial of an ICS/LABA combination?
More than one answer allowed.
 a. FEV1 <50% predicted
 b. MRC Score 3 or below
 c. Smoker
 d. 2 exacerbations in the last 12 months
 e. BMI under 21


Top of page | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | References and Abbreviations |

6. Which of the following would be appropriate first line treatment in the management of an exacerbation where there was mucopurulent sputum?
More than one answer allowed.
 a. Ciprofloxacin 500mg bd
 b. Prednisolone 30mg daily for 7-14 days
 c. Amoxicillin 500mg tds 5 days / or Clarithromycin if allergic to penicillin
 d. Increase dose of inhaled steroid


Top of page | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | References and Abbreviations |

7. Which of the following interventions has been proven to be the most effective and cost effective at reducing FEV1 decline?
a. Pulmonary rehabilitation
b. Smoking cessation
c. Use of inhaled steroids
d. Long term oxygen


Top of page | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | References and Abbreviations |

8. Which of the following factors would influence your decision to refer for pulmonary rehabilitation?
a. Smoker
b. Social isolation
c. Over 65
d. MRC grade 3 or above.


Top of page | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | References and Abbreviations |

9. When would you refer a patient for assessment for long term oxygen therapy (LTOT)?
a. BMI<20
b. FEV1 <50% plus two exacerbations in last year
c. MRC 3 or above
d. Oxygen saturation 92% or less


Top of page | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | References and Abbreviations |

10. Which or the following immunisations would you consider in a patient with COPD?
More than one answer allowed.
 a. Tetanus
b. Pneumococcal vaccine
 c. Typhoid
 d. Influenza Vaccine
This series of resources has been produced as a service to primary care by the Primary Care Respiratory Society UK (PCRS-UK) and has been supported by an educational grant from Allen & Hanburys, AstraZeneca UK Ltd and Boehringer Ingelheim Ltd/Pfizer Ltd. The views expressed in the materials are not necessarily those of either the sponsors or the Primary Care Respiratory Society UK (PCRS-UK). © PCRS-UK